Systemic-first management of HER2-positive brain metastases
With Enhertu and tucatinib controlling brain metastases in most patients, radiation could be reserved for those who do not respond, sparing cognitive side effects.
DESTINY-Breast12 (intracranial ORR 72%) and HER2CLIMB support systemic therapy as initial management for asymptomatic or small brain metastases, with radiosurgery held in reserve.
Pages like this
not linked directly; found by shared links- PairingTucatinib + trastuzumab + capecitabine for brain metastases
Shares HER2CLIMB, HER2-positive brain metastases, Tucatinib, HER2-positive breast cancer.
- IdeaPrevention trials aimed only at brain metastasis
Shares HER2CLIMB, HER2-positive brain metastases, Tucatinib, The brain: barrier and sanctuary.
- IdeaUse the brain's own transport door to carry antibody drugs across
Shares HER2-positive brain metastases, Tucatinib, The brain: barrier and sanctuary, Trastuzumab deruxtecan.
- PersonNancy U. Lin
Shares HER2CLIMB, Tucatinib, HER2-positive breast cancer.
- IdeaBrain metastases included by default in every solid-tumour trial
Shares Tucatinib, The brain: barrier and sanctuary, Trastuzumab deruxtecan, HER2-positive breast cancer.
- IdeaStop excluding brain metastases from cancer trials
Shares HER2CLIMB, HER2-positive brain metastases, The brain: barrier and sanctuary.
- IdeaTreat brain metastases as a disease with its own trials programme
Shares Tucatinib, The brain: barrier and sanctuary, SBRT / SABR (stereotactic radiotherapy), HER2-positive breast cancer.
- TrialHER2CLIMB-02
Shares Tucatinib, HER2-positive breast cancer.